US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.18 — a beat of 55.6%.
Analysts rate InflaRx N.V. a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $7.52.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 5.39% |
| 683 Capital Management LLC | 2.25% |
| Bank of America Corp | 1.34% |
| Eversept Partners, LP | 1.19% |
| Morgan Stanley - Brokerage Accounts | 0.80% |
| Marshall Wace Asset Management Ltd | 0.38% |
| T3 Companies, LLC | 0.22% |
| Squarepoint Ops LLC | 0.20% |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for InflaRx N.V. — free to start.
Google PlayApp StoreData updated 2026-08-05.